Table 1. Clinical details of LCH patients.
Disease categories (Group 1–3) correspond to Histiocyte Society groups used in the LCH-III treatment protocol. Group 4 includes patients with single non-risk lesions.
Chemotherapy abbreviations:
LCHIII-1A: vinblastine, prednisone, mercaptopurine.
LCHIII-1B: vinblastine, prednisone, mercaptopurine, methotrexate.
VP-16: etoposide
LCH-A1: vinblastine, prednisone, mercaptopurine (Histiocyte Society adult LCH protocol).
| Table 1A. Clinical Details of LCH Patients – Biopsy Samples | ||||||
|---|---|---|---|---|---|---|
|
Patient Number |
Age (years) | Gender | Disease Category |
Sites of LCH Lesions | Biopsy Site | Chemotherapy |
| 1 | 2.3 | M | 2 | single skull (occipital), recurrent tibia |
tibia | N |
| 2 | 0.95 | M | 3 | multifocal skull, orbit | orbit | N |
| 3 | 0.9 | F | 1 | skin, lungs, multiple skull, mastoid, gingiva |
mastoid | LCHIII-IA |
| 4 | 6.2 | F | 4 | single skull (parietal) | parietal skull | N |
| 5 | 2.8 | M | 4 | single skull (parietal) | parietal skull | N |
| 6 | 5.5 | F | 2 | pelvis | pelvis | N |
| 7 | 0.8 | M | 2 | orbit, skin | skin | N |
| 8 | 1.8 | M | 4 | mandible | mandible | N |
| 9 | 4.9 | F | 2 | skin, bone | scalp | N |
| 10 | 14 | M | 4 | single skull (parietal) | parietal skull | N |
| 11 | 6 | M | 3 | single skull (frontal) | frontal skull | N |
| 12 | 0.9 | F | 3 | mastoid | mastoid | N |
| 13 | 2.1 | F | 1 | mandible, skull, vertebrae, recurrent orbit |
orbit | LCHIII-IB |
| 14 | 5.9 | M | 4 | single skull | skull | N |
| Table 1B. Clinical Details of LCH Patients – Plasma Samples | ||||||
|---|---|---|---|---|---|---|
|
Patient Number |
Age (years) | Gender | Disease Category |
Sites of LCH Lesions | Chemotherapy | Therapy Details |
| 3 | 0.7 | F | 1 | skin, lungs, multiple skull, mastoid, gingival |
N | |
| 3 | 0.9 | F | 1 | skin, lungs, multiple skull, mastoid, gingival |
Y | LCHIII - IA |
| 15 | 0.1 | F | 1 | skin, liver, bone marrow | N | |
| 15 | 0.4 | F | 1 | skin, liver, bone marrow | Y | LCHIII - IA |
| 16 | 0.5 | F | 1 | skin, multiple skull, multifocal bone, liver, bone marrow |
N | |
| 16 | 0.6 | F | 1 | skin, multiple skull, multifocal bone, liver, bone marrow |
Y | VP-16, LCHIII-IA |
| 17 | 56 | F | 1 | lung, lymph node | N | |
| 18 | 0.4 | F | 1 | skin, lung, multiple skull | N | |
| 19 | 1.9 | M | 1 | skin, multiple skull, mastoid - refractory |
Y | LCHIII - IB |
| 20 | 57 | M | 1 | lung, skin, jaw | Y | prednisone |
| 21 | 38 | F | 1 | skin, lung | N | |
| 22 | 43 | F | 1 | lung, multifocal bone | Y | LCH-A1 |
| 23 | 50 | F | 1 | skin, mouth, lungs | N | |
| 24 | 38 | F | 1 | LN, malig histiocytosis | N | |
| 25 | 11 | F | 1 | lung, LN, multifocal bone bone | Y | VCR, Ara-C |
| 26 | 34 | F | 1 | mastoid, lung | N | |
| 38 | 31 | F | 1 | lung | Y | prednisone |
| 27 | 7.8 | F | 3 | skull (frontal), femur | N | surgery |
| 28 | 1.4 | F | 3 | multifocal bone | N | |
| 29 | 5.9 | M | 3 | pituitary (relapse), history of liver, multiple skull |
N | |
| 30 | 38 | F | 3 | multifocal bone, pituitary | N | |
| 31 | 3.6 | M | 3 | pituitary (relapse) | N | |
| 32 | 44 | F | 3 | thymus, pituitary | N | |
| 33 | 24 | F | 3 | degenerative CNS | N | |
| 34 | 2.8 | M | 3 | pituitary | N | |
| 35 | 22 | M | 3 | brain, skull (base) | N | surgery |
| 36 | 3.7 | M | 3 | single bone (orbit) | N | surgery |
| 37 | 2.9 | M | 4 | skull (parietal) | N | surgery |
| 39 | 2.2 | M | 4 | single skull (occiput) | N | surgery |
| 40 | 0.3 | M | 4 | skin only | N | |
| 41 | 3.5 | F | 4 | skin only | N | |
| 42 | 0.1 | F | 4 | skin only | N | |
| 43 | 6.1 | F | 4 | single skull (parietal) | N | surgery |
| 44 | 5 | F | 4 | single bone (femur) | N | surgery |
| 45 | 7.9 | M | 4 | single bone (femur) | N | surgery |
| 46 | 8.7 | M | 4 | single bone (femur) | N | surgery |